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Association of reduced red
blood cell deformability and
diabetic nephropathy
To the Editor: In a recent issue of Kidney International,
Brown et al [1] reported significant data concerning red
blood cell deformability and and renal function decline
in type 2 diabetic patients. They propose a smart phys-
iopathologic explanation using the “AGEs” hypothesis
that seems relevant and convincing. However, one can
suppose that AGEs are not the only pathway involved in
both reduction of red blood cell deformability and pro-
gression of renal failure in this population. Indeed, red
blood cell deformability is reduced in diabetic patients [2,
3]. This reduction is correlated with a decrease in Na,K-
ATPase activity in red blood cells. The reduction of both
Na,K-ATPase activity and red blood cell deformability is
proportional to the simultaneous decrease in C-peptide
plasma concentration in type 2 diabetic patients [4] and
can be corrected by C-peptide administration [5]. Besides
being related to NO-mediated direct effects on the re-
sistance vessels, C-peptide’s circulatory effects involve
rheologic factors. This effect is blockable by ouabain,
indicating that it is mediated in part by a restoration
of erytheocyte Na,K-ATPase activity [6]. Furthermore,
C-peptide is involved in stimulation of eNOS in renal
capillary endothelial cells [7], which may modify the
glomerular function, including diminished albumin ex-
cretion. Improved renal function may also be a con-
sequence of stimulation by C-peptide of glomerular or
tubular Na+, K+-ATPase activity [8, 9]. Last, but not
least, a clinical study of a large cohort of type 2 dia-
betic patients showed that onset of diabetic nephropathy
was correlated with the residual plasma C-peptide levels
[10]. Altogether, these are strong arguments to complete
Brown’s “AGEs” hypothesis by measuring C-peptide lev-
els in a future study in this population.
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Reply from the Authors
We wish to thank Rebsomen and Tsimaratos for their
interest in our study, and would like to respond to points
raised in their letter to the Editor. While we recognize
that Na,K-ATPase activity influences RBC deformability
(RBC-df), and that basal plasma C-peptide concentration
has a beneficial effect on RBC-df by a mechanism involv-
ing Na,K-ATPase [1], we do not believe that C-peptide
deficiency plays a role in our study.
The effect of absolute C-peptide deficiency on RBC-df
has been reported in type 1 diabetic subjects [2]. Fur-
thermore, significantly reduced (but not absent) levels of
C-peptide have been shown to occur only in type 2 di-
abetic subjects who require insulin treatment, and that
C-peptide levels are normal in type 2 subjects who do not
require insulin for glucose control. All diabetic subjects in
our study were type 2, and none required insulin to con-
trol blood glucose. We measured RBC-df in two groups
of nondiabetic subjects with renal disease who served as
control. In these nondiabetic control subjects there was
significant impairment in RBC-df. In fact, impairment in
RBC-df in these subjects with end-stage renal disease (on
maintenance hemodialysis) was not different from their
diabetic counterparts.
Although C-peptide was not measured in our study, we
presume that its concentration was not deficient in either
our nondiabetic control or non–insulin-requiring type 2
diabetic subjects.
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Reverse epidemiology of blood
pressure in dialysis patients
To the Editor: Agarwal implies that the paradoxical
associations found between higher blood pressure (BP)
values and better survival are limited to prevalent dialy-
sis patients [1]. We recently studied a 15-month cohort of
40,933 hemodialysis patients and found that high predial-
ysis systolic BP conferred survival advantages even after
adjustment for dialysis vintage categories, among others
[2]. Shoji et al showed that intradialysis hypotension and
orthostatic hypotension after hemodialysis are significant
and independent factors affecting mortality in hemodial-
ysis patients [3]. A recent study by Lopez-Gomez et al
showed that a high predialysis BP was frequently ob-
served in those hemodialysis patients who had the highest
interdialytic weight gain, increased food intake, better nu-
tritional status, and improved clinical outcome, including
better survival [4]. Hence, we caution against categoric
dismissal of the reverse epidemiology of BP, only because
they appear counterintuitive based on observations from
the general population. Indeed, the reverse epidemiol-
ogy is not restricted to BP, but has also been observed
with regard to obesity, hypercholesterolemia, and hyper-
homocysteinemia, among others [5].
Moreover, the reverse epidemiology is not restricted
to dialysis patients but may also exist in over 20 mil-
lion Americans, including patients with heart failure,
advanced age, malignancies, AIDS, and several other
chronic disease states [5]. Therefore, we believe that
the reverse epidemiology phenomenon deserves a more
global and inclusive point of view. Further studies are
needed to explore mechanisms behind such paradoxic as-
sociations, and to assess what BP range is the best for dial-
ysis patients. Examining methods to improve nutritional
status and inflammation in dialysis and other similar pa-
tient populations may be a crucial step to that direction.
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Many of the answers that explain the paradoxic associa-
tion between low blood pressure (BP) and high mortality
lie within the studies that Kalantar-Zadeh et al cite. First,
the large study they have performed has only a two-year
follow-up, which may be insufficient to reveal hyperten-
sion as a risk factor for cardiovascular disease [1]. Cor-
rection for the dialysis vintage does not remove the bias
that exists in a prevalent cohort study; antihypertensive
drug use or cardiovascular disease, especially heart fail-
ure, have not been considered when studying the impact
of BP on total mortality. For example, patients with heart
failure may have a greater mortality despite a lower BP
compared to patients without heart failure on hemodial-
ysis [2]. A relationship between good nutrition and hy-
pertension suggests that favorable clinical characteristics
are associated with a higher BP, but does not suggest that
lowering BP or limiting sodium intake in those with hy-
pertension is associated with worse outcomes [3]. Shoji
et al relate intradialytic—not interdialytic—hypotension
as a risk factor for mortality [4]. Epidemiology helps us
understand the nature and scope of the problem. Causal-
ity cannot be deduced from paradoxically relating low
BP to increased mortality. The correlation of lower BP
with short-term mortality may simply be a reflection of a
higher level of sickness. Controlling hypertension is pro-
tective in long-term cohort studies [5], and in studies that
examine the influence of systolic hypertension on car-
diovascular events rather than total mortality [6]. Hence,
lowering BP through nonpharmacologic and pharmaco-
logic means should be a key element of management of
